



KAREN TOFFLER CHARITABLE TRUST FACT SHEET

The Karen Toffler Charitable Trust is a nonprofit organization working to revolutionize medical research, education, and technology. To achieve the world-changing breakthroughs our legacy demands, we create strong partnerships with cutting-edge organizations and promising young researchers through the annual funding of projects. Our focus is on early-stage research that advances the medical field in profound, high-impact ways.

Our audacious goals are only possible with the support of our partners. To maximize our impact on the world, we strive to connect our network more deeply to foster new ways of thinking and problem-solving. We draw on their expertise, perspectives, and ideas as we work to find solutions to humanity's most difficult problems.

FOCUS AREAS

Interconnected Ideas

Through the funding awarded by the Karen Toffler Charitable Trust, disparate focus areas and research endeavors are connected to drive exponential impact. Grantees gain necessary funding as well as connections to relevant projects outside their immediate area of study that could benefit from their focused discovery and insights. By strengthening their funding support and research networks, scientists, researchers, and institutions discover new ways of problem-solving together.

Early-Stage Research

The Karen Toffler Charitable Trust has built a future-focused framework that allows us to be a bridge from early-stage ideas to a stage of research where funding traditionally is more obtainable. We back our commitment to groundbreaking science with meaningful financial support. The impact is seen in the incredible work being done by individuals and organizations that might otherwise be unable to move their work forward.

FUNDING PRIORITIES

Dementia Research

Around the world, approximately 50 million people have been diagnosed with dementia, a group of brain disorders that cause memory, thinking, behavior, and coordination to deteriorate. Alzheimer's disease is the most common cause. Every year, nearly 10 million new cases emerge. As the population ages, the numbers are projected to rise substantially. The Karen Toffler Charitable Trust funds research that will lead to fewer cases, better care, and new treatments.

Rare and Underfunded Conditions

The Karen Toffler Charitable Trust funds little-known and micro areas of research that show promise for understanding and solving pressing and unexplained medical issues on a macro level. By supporting research for rare diseases such as Guillain-Barre syndrome or Idiopathic Thrombocytopenic Purpura (ITP), as well as emerging infectious disease surveillance, we help to care for those who may be impacted now and create connections to the breakthroughs essential for the future health and security of humanity.

PROGRAMS & PARTNERSHIPS

Toffler Scholar Program

Through partnerships with leading universities, the Toffler Scholar program supports promising young medical researchers, physicians, and scientists who are at a pivotal point in their careers. With funding and a vital, relevant network, recipients have the resources they need to continue their groundbreaking work and develop into experienced professionals.

[Learn more about the Toffler Scholar Program.](#)

Toffler Grant Program

Through strategic annual grants, the Toffler Grant program supports medical research organizations that have demonstrated high-impact potential and a need for financial and network support. For those who challenge conventional thinking in the effort to create a healthier future, the Toffler Grant program is a path to the next stage of research, discovery, and impact.

[Learn more about the Toffler Grant Program.](#)

LEADERSHIP

Rebecca Bartoli, Executive Director

Dr. Peter Katona, Trustee

Deborah Westphal, Business Advisor

Russ Glassman, CPA, Trustee

Tom Johnson, Trustee

LOCATION

12121 Wilshire Blvd., Suite 810
Los Angeles, CA 90025

FOUNDATION FACTS

Total Funding

(From 2016 to 2021):

\$1,151,500.00

Partner

Universities:

9

Toffler Scholars and

Leadership Awards:

28

[Full Financial Statement, Year ended December 31, 2020](#)